What do systematic reviews say?

Pregabalin vs placebo at end of treatment

Pregabalin leads to higher 50% pain reduction compared with placebo at end of treatment (high certainty).

• Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
  RR 1.59 [1.33, 1.9]
  5 studies · 3256 participants
  High

Pregabalin vs placebo at end of treatment

Pregabalin leads to higher patient Global Impression of Change of 'much' or 'very much' improved compared with placebo at end of treatment (high certainty).

• Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
  RR 1.38 [1.23, 1.55]
  5 studies · 3183 participants
  High

Pregabalin vs placebo at end of treatment

• Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 3195 participants
  High

Pregabalin vs placebo at end of treatment

• Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 3139 participants
  High

Pregabalin vs placebo at end of treatment

Pregabalin leads to higher withdrawal due to adverse events compared with placebo at end of treatment (high certainty).

• Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
  RR 1.68 [1.36, 2.07]
  5 studies · 3259 participants
  High

Pregabalin vs placebo at end of treatment

Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).

• Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
  RR 1.03 [0.71, 1.49]
  4 studies · 2729 participants
  Moderate

Pregabalin vs placebo at end of treatment

Pregabalin leads to higher dizziness reported to be an adverse event compared with placebo at end of treatment (high certainty).

• Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
  RR 3.77 [3.06, 4.63]
  5 studies · 3257 participants
  High